Morgan Stanley lowered the firm’s price target on Y-mAbs Therapeutics to $11 from $12 and keeps an Underweight rating on the shares. Danyelza sales in Q2 were in line with consensus as weakness in the U.S. was offset by a rebound in ex-U.S. sales and management lowered 2024 net product sales guidance reflecting headwinds in 1H24, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB: